HCM ▲ +1.1% - HUTCHMED (China) Limited $HCM - HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy HUTCHMED signed a licensing agreement with GSK for a KRAS-EGFR-antibody conjugate cancer therapy, marking an expansion of the company's partnership with the pharmaceutical giant. The deal validates HUTCHMED's pipeline in targeted oncology and provides potential near-term revenue through upfront and milestone payments, driving the modest gain in today's trading. 03-SEP-2026 12:00 AM ET